Literature DB >> 19776095

Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study.

Stephan Polterauer1, Christoph Grimm, Veronika Seebacher, Nicole Concin, Christian Marth, Caroline Tomovski, Heinrich Husslein, Heinz Leipold, Katrin Hefler-Frischmuth, Clemens Tempfer, Alexander Reinthaller, Lukas Hefler.   

Abstract

INTRODUCTION: To evaluate pretherapeutic plasma fibrinogen levels as a prognostic parameter in patients with epithelial ovarian cancer (EOC). Materials and Methods. In the present multicenter study, pretherapeutic plasma fibrinogen levels were evaluated in 422 patients with EOC. Plasma fibrinogen levels were correlated with clinicopathological parameters and patient survival.
RESULTS: The mean (standard deviation) pretherapeutic plasma fibrinogen level was 450.0 (150.1) mg/dl. Elevated plasma fibrinogen levels were associated with advanced tumor stage (p = .01) and the presence of a postoperative residual tumor mass (p < .001), but not with histological grade (p = .1) and histological type (p = .8). In a multivariate Cox regression model, tumor stage (p < .001 and p < .001), postoperative residual tumor mass (p = .001 and p = .008), and plasma fibrinogen level (p < .001 and p = .002), but not histological type (p = .8 and p = .2), patient age (p = .9 and p = .9), and serum cancer antigen 125 (p = 0.2 and p = 0.3) and C-reactive protein (p = .2 and p = .3) levels, were associated with disease-free and overall survival, respectively. Histological grade was associated with overall but not with disease-free survival (p = .01 and p = .8), respectively.
CONCLUSIONS: Pretherapeutic plasma fibrinogen levels can be used as an independent prognostic parameter in patients with EOC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776095     DOI: 10.1634/theoncologist.2009-0079

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  47 in total

1.  Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.

Authors:  Ana Custodio; Antonio J López-Farré; José J Zamorano-León; Petra J Mateos-Cáceres; Carlos Macaya; Trinidad Caldés; Miguel de la Hoya; Elena Olivera; Javier Puente; Eduardo Díaz-Rubio; Pedro Pérez-Segura
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-07       Impact factor: 4.553

2.  High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma.

Authors:  Jun Du; Jian-Hua Zheng; Xu-Sheng Chen; Qing Yang; Yan-Hui Zhang; Lei Zhou; Xin Yao
Journal:  Int J Clin Oncol       Date:  2012-05-19       Impact factor: 3.402

3.  Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer.

Authors:  Edgar Selzer; Anja Grah; Gregor Heiduschka; Gabriela Kornek; Dietmar Thurnher
Journal:  Wien Klin Wochenschr       Date:  2016-02-26       Impact factor: 1.704

4.  Prognostic significance of preoperative fibrinogen in patients with colon cancer.

Authors:  Zhen-Qiang Sun; Xiao-Na Han; Hai-Jiang Wang; Yong Tang; Ze-Liang Zhao; Yan-Li Qu; Rui-Wei Xu; Yan-Yan Liu; Xian-Bo Yu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

Review 6.  Secreted proteins as a fundamental source for biomarker discovery.

Authors:  Miroslava Stastna; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2012-01-19       Impact factor: 3.984

Review 7.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

8.  Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry.

Authors:  You-Kang Chang; Yu-Heng Lai; Yen Chu; Ming-Cheng Lee; Chun-Yao Huang; Semon Wu
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

9.  Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Authors:  Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan
Journal:  J Transl Med       Date:  2011-03-04       Impact factor: 5.531

Review 10.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.